CClinicalTrials.gg
Status unknownNCT05465746Updated Jul 20, 2022

Cumulative Blood Pressure Load and Left Ventricular Mass

An observational study in Arterial Hypertension, sponsored by Instituto Ecuatoriano del Corazón. Status unknown at 1 site in Ecuador. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by Instituto Ecuatoriano del Corazón · Observational

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
40 Years to 79 Years
Sex
All
01

Study summary

Delay in the diagnosis of systemic arterial hypertension (SAH) causes morbid hypertensive status with target organ damage (TOD). Screening and surveillance of SAH used to be performed through self-measurement of blood pressure (SMBP) or routinary in clinic blood pressure measurement (CBPM).

It is essential to determine the correlation between the cumulative blood pressure load through ABPM and the left ventricular mass identified by three-dimensional transthoracic ultrasound (3D-TTE). We postulate a directly proportional and statistically significant association between cumulative blood pressure load and left ventricular mass (LVM).

Read the detailed description

Delayed diagnosis of SAH causes a morbid hypertensive state, with target-organ damage (TOD): brain, kidney, and heart. An early diagnosis and proper follow-up of patients with SAH prevents and reduces comorbidities associated with TOD. Screening and follow-up of SAH are traditionally performed by routine self-monitoring of blood pressure (HBPM) or clinic blood pressure measurement (CBPM).

Ambulatory blood pressure monitoring (ABPM) consists of measuring BP every fifteen and thirty minutes for twenty-four hours, using a sphygmomanometer adapted to a portable monitor, which led to the recognition of SAH phenotypes often not identified through SMBP or CBPM. The ABPM offers three types of information: a) the mean BP in twenty-four hours, day and night; b) BP variability; and c) cumulative BP load. Cumulative BP load is the percentage of BP measurements above 135/85 mmHg.

Increased LVM is a consequence of chronic hypertension and early sign of TOD at the cardiac level. It has been shown that the variability in nocturnal diastolic BP correlates significantly with LVM, independently of mean BP load. It is likely that an elevated BP load according to ABPM correlates with higher TOB; however, at the moment, there is no standardized value of BP load that allows predicting the increase in the LVM. For this reason, a standardized cut-off of cumulative BP load is helpful for understanding ABPM in the screening SAH.

02

Conditions studied

  • Arterial Hypertension

Browse trials for

Keywords

  • Ambulatory blood pressure monitoring
  • Blood pressure
  • Target organ damage
  • Left ventricular mass
  • Transthoracic echocardiography
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 964 are open to participants now.

This study's planned enrollment of 80 is below the median of 210 across 1,358 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

This is the only study on the registry with Instituto Ecuatoriano del Corazón as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with an indication of SAH screening.

Inclusion criteria

  • Both sex
  • Between 40 and 79 years old.
  • Low or moderate cardiovascular risk according to the 3American Heart Association (AHA) criteria.

Exclusion criteria

Exclusion Criteria:

  • Patients with TOD defined as: the history of cerebrovascular event (CVD); chronic kidney disease (CKD) with glomerular filtration rate (GFR) \<30 mL/min/1.73 m2 or under replacement therapy (renal dialysis).
  • History of chronic liver disease with a Child-Pugh B or C.
  • Dependence on alcohol or psychotropic drugs.
  • History of cancer, regardless of stage or time of treatment.
  • Patients who do not wish to participate in this study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults with an indication of SAH screening

    Patients who attend the physician's office or the emergency room (ER) with signs and symptoms of high systemic arterial blood pressure will be indicated for ABPM and TTE

    Diagnostic Test: 24-hour ambulatory blood pressure monitoring (ABPM) · Diagnostic Test: Three-dimensional transthoracic echocardiography

Interventions

  • Diagnostic test24-hour ambulatory blood pressure monitoring (ABPM)

    Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load

  • Diagnostic testThree-dimensional transthoracic echocardiography

    Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.

06

What researchers measure

Primary outcomes

  1. 24-hour systolic and diastolic blood pressure (SBP & DBP)

    The ABPM study will allow obtaining results of the mean BP in 24 hours, day and night; BP variability; and the pressure load. According to the international HBP guideline, normal BP will be considered below 135/85 mmHg during the twenty-four hours or during the day or below 120/70 mmHg at night. BP load is the percentage of BP measurements above 135/85 mmHg.

    Time frame: 24 hours

  2. Left ventricular mass index (LVMI)

    LVMI will be considered high when it exceeds 115 g/m2 of the body surface in men and 95 g/m2 in women. Each 3D-TTE will be performed by an echocardiographic cardiologist with experience in more than 5,000 3D-TTEs performed on adults annually. For the LVMI estimate to be as unbiased as possible, she will perform the 3D-TTE blind to any clinical history before completing the ABPM.

    Time frame: 30 minutes

07

Study locations

1 of 1 sites recruiting
  • Instituto Ecuatoriano del Corazón
    Guayaquil, Guayas 090112, Ecuador
    Recruiting
08

References and documents

Publications

  • Cuspidi C, Sala C, Casati A, Bombelli M, Grassi G, Mancia G. Clinical and prognostic value of hypertensive cardiac damage in the PAMELA Study. Hypertens Res. 2017 Apr;40(4):329-335. doi: 10.1038/hr.2016.153. Epub 2016 Nov 17. PubMed 27853165 ↗
  • Mustafa ER, Istratoaie O, Musetescu R. Blood Pressure Variability and Left Ventricular Mass in Hypertensive Patients. Curr Health Sci J. 2016 Jan-Mar;42(1):47-50. doi: 10.12865/CHSJ.42.01.07. Epub 2016 Mar 29. PubMed 30568812 ↗
  • O'Brien E, White WB, Parati G, Dolan E. Ambulatory blood pressure monitoring in the 21st century. J Clin Hypertens (Greenwich). 2018 Jul;20(7):1108-1111. doi: 10.1111/jch.13275. PubMed 30003702 ↗
  • Uallachain GN, Murphy G, Avalos G. The RAMBLER study: the role of ambulatory blood pressure measurement in routine clinical practice: a cross-sectional study. Ir Med J. 2006 Oct;99(9):276-9. PubMed 17144238 ↗
  • Jones NR, McCormack T, Constanti M, McManus RJ. Diagnosis and management of hypertension in adults: NICE guideline update 2019. Br J Gen Pract. 2020 Jan 30;70(691):90-91. doi: 10.3399/bjgp20X708053. Print 2020 Feb. No abstract available. Erratum In: Br J Gen Pract. 2020 Feb 27;70(692):111. doi: 10.3399/bjgp20X708461. PubMed 32001477 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05465746
Lead sponsor
Instituto Ecuatoriano del Corazón
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jul 1, 2022
Primary completion
Dec 31, 2022 (estimated)
Completion
Feb 28, 2023 (estimated)
Last update
Jul 20, 2022

Study contacts

Patricia Delgado-Cedeño, MD
Contact
pdelgadodevargas@gmail.com
+593 997829415
Miguel Puga-Tejada, MD
Contact
miguel.puga01@gmail.com
+5491165003311
Patricia Delgado-Cedeño, MD
principal investigator · Instituto Ecuatoriano del Corazón

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion